---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-23-000046"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:26:20.156703+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amphastar Q1 revenues $140M (+16% YoY); GAAP EPS $0.50, adj. EPS $0.62

## Summary
- Net revenues $140.0M vs $120.4M YoY; GAAP net income $26.0M ($0.50 diluted EPS).
- Adjusted non-GAAP net income $32.1M ($0.62 diluted EPS), up from $24.6M ($0.47) YoY.
- Key growth drivers: glucagon, Primatene MIST, epinephrine; new launches include regadenoson and intranasal naloxone.
- Proposed BAQSIMI acquisition noted as transformative for diabetes portfolio and branded product strategy.

## SEC filing metadata
- accession: 0001297184-23-000046
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718423000046/0001297184-23-000046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718423000046/amph-20230509x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-23-000046
- JSON: https://secwatch.observer/filing/0001297184-23-000046.json
- Plain text: https://secwatch.observer/filing/0001297184-23-000046.txt

## Key facts
- Earnings Releases
  Amphastar Pharmaceuticals, Inc. reported three months ended March 31, 2023 results: revenue 140.0 million, net income 26.0 million, EPS 0.50.
  - Period: three months ended March 31, 2023
  - Revenue: 140.0 million
  - Net income: 26.0 million
  - EPS: 0.50
  - Result: reported results
  source text: Reports Net Revenues of $140.0 Million for the Three Months Ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1297184/000129718423000046/0001297184-23-000046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.